Loring Wolcott & Coolidge Fiduciary Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-26	Closed	-$2K	–	711
2019 Q2	$2K	Buy	+26	New	+$1.92K	﹤0.01%	663
2017 Q4	–	Sell	-13	Closed	-$1K	–	817
2017 Q3	$1K	Buy	+13	New	+$1.03K	﹤0.01%	720

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's LGND Position: Q3 2019 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 26 shares — an estimated $2K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in LGND in Q3 2017 and held it in 2 quarters. The position peaked at $2K in Q2 2019. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 26 Ligand Pharmaceuticals shares in Q3 2019, an estimated $2K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 2 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Ligand Pharmaceuticals position peaked at $2K in Q2 2019.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.